Bexsero

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunogenicityWomen

87 competitors in Immunogenicity

#DrugCompanyPhaseTrials

1

Perjeta

Roche

Phase 3

22

Rabies Vaccine

Novartis

Phase 3

123

Prolia

OOrganon and Co

Phase 3

24

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

35

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

26

Rsvpref

Pfizer

Phase 3

57

Gardasil

Merck & Co.

Phase 3

78

PCV21

Sanofi

Phase 3

19

Opfolda

Johnson & Johnson

Phase 3

110

Pentavalent Vaccine

GSK

Phase 3

1Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity8 trials

Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04166656·84 enrolled

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Completed·GSK·Phase 3·NCT02173704·225 enrolled

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Completed·GSK·Phase 2·NCT02212457·1,063 enrolled

Show 5 more trials

A Phase I Clinical Trial to Assess the Safety and Immunogenicity of DX-104

Not yet recruiting·SShanghai Yuguan Biotech Co., Ltd.（Delonix Bioworks)·Phase 1·NCT07395739·30 enrolled

A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults

Completed·GSK·Phase 1·NCT02491463·73 enrolled

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population

Unknown status·SSt George's, University of London·Phase 4·NCT03682939·55 enrolled

Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults

Completed·CCanadian Immunization Research Network·Phase 4·NCT02583412·120 enrolled

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Terminated·Pfizer·Phase 2·NCT04645966·326 enrolled

Women1 trial

BIYELA - Bexsero Immunisation in Young Women in Africa

Active, not recruiting·UUniversity of Washington·Phase 3·NCT06446752·1,100 enrolled

Vaccine1 trial

Meningococcal B Vaccine in Patients with Asplenia

Recruiting·MMedical University of Vienna·Phase 2·NCT06025487·80 enrolled

Genital Herpes1 trial

A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes

Completed·Moderna·Phase 1/2·NCT06033261·365 enrolled

Infections, Meningococcal1 trial

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed·GSK·Phase 3·NCT03621670·1,196 enrolled

Details

Drug Info

Related News